Thus, the stabilized β‐catenin protein translocated to the nucleus and subsequently upregulates its downstream targets, which facilitates ECM accumulation and HCC progression, which will help us further understand the roles of FGF9 in NASH‐driven HCC. The gene discussed is FGF9; the disease is metabolic dysfunction-associated steatohepatitis.